Skip to main content
Have a personal or library account? Click to login
AI-Guided Precision Medicine: A European Biotechnology Thematic Network Association Perspective on Multi-Omics, Digital Sensors, Medical Assessment, and Ethical-Regulatory Challenges Cover
Read online

References

  1. Adib K, Letchford N, Dunning HE, Salama N, Tolias Y, De Barros J, et al. Governance of artificial intelligence for health systems, WHO European Region. Bull World Health Organ. 2026;104(6):374–85. doi:10.2471/BLT.25.294978.
  2. Warraich HJ, Tazbaz T, Califf RM. FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine. JAMA. 2025;333(3):241–7. doi:10.1001/jama.2024.21451.
  3. Windecker D, Baj G, Shiri I, Kazaj PM, Kaesmacher J, Gräni C, et al. Generalizability of FDA-Approved AI-Enabled Medical Devices for Clinical Use. JAMA Netw Open. 2025;8(4):e258052. doi:10.1001/jamanetworkopen.2025.8052.
  4. König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? Eur Respir J. 2017;50(4):1700391. doi:10.1183/13993003.00391-2017.
  5. Lohse S. Mapping uncertainty in precision medicine: A systematic scoping review. J Eval Clin Pract. 2023;29(3):554–64. doi:10.1111/jep.13789.
  6. Duffy DJ. Problems, challenges and promises: perspectives on precision medicine. Brief Bioinform. 2016;17(3):494–504. doi:10.1093/bib/bbv060.
  7. Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, et al. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2022;84:242–54. doi:10.1016/j.semcancer.2021.05.026.
  8. Beccia F, Hoxhaj I, Castagna C, Strohäker T, Cadeddu C, Ricciardi W, et al. An overview of Personalized Medicine landscape and policies in the European Union. Eur J Public Health. 2022;32(6):844–51. doi:10.1093/eurpub/ckac103.
  9. Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J, et al. Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer. 2022;176:70–7. doi:10.1016/j.ejca.2022.09.005.
  10. Bergman A, Wachter RM, Emanuel EJ. A Licen-sure Framework for Autonomous Clinical AI. JAMA. 2026;335(20):1751–4. doi:10.1001/jama.2026.5483.
  11. Wang L, Li J, Zhuang B, Huang S, Fang M, Wang C, et al. Accuracy of Large Language Models When Answering Clinical Research Questions: Systematic Review and Network Meta-Analysis. J Med Internet Res. 2025;27:e64486. doi:10.2196/64486.
  12. Han R, Acosta JN, Shakeri Z, Ioannidis JPA, Topol EJ, Rajpurkar P. Randomised controlled trials evaluating artificial intelligence in clinical practice: a scoping review. Lancet Digit Health. 2024;6(5):e367–73. doi:10.1016/S2589-7500(24)00047-5.
  13. Adib K, Dunning HE, Letchford N, Salama N, Tolias Y, Barros JD, et al. Artificial intelligence in health systems of the WHO European region: implementation, applications, opportunities, and barriers. Int J Med Inform. 2026;218:106532. doi:10.1016/j.ijmedinf.2026.106532.
  14. Marra A, Morganti S, Pareja F, Campanella G, Bibeau F, Fuchs T, et al. Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives. Ann Oncol. 2025;36(7):712–25. doi:10.1016/j. annonc.2025.03.006.
  15. Huang JD, Wang J, Ramsey E, Leavey G, Chico TJA, Con-dell J. Applying Artificial Intelligence to Wearable Sensor Data to Diagnose and Predict Cardiovascular Disease: A Review. Sensors (Basel). 2022;22(20):8002. doi:10.3390/s22208002.
  16. Cabral BP, Braga LAM, Conte Filho CG, Penteado B, Freire de Castro Silva SL, Castro L, et al. Future Use of AI in Diagnostic Medicine: 2-Wave Cross-Sectional Survey Study. J Med Internet Res. 2025;27:e53892. doi:10.2196/53892.
  17. Blease C, Kharko A, Locher C, DesRoches CM, Mandl KD. US primary care in 2029: A Delphi survey on the impact of machine learning. PLoS One. 2020;15(10):e0239947. doi:10.1371/journal.pone.0239947.
  18. Amarapathy S, Tyagi S. Multi-omics applications in health and diseases. Prog Mol Biol Transl Sci. 2026;221:43–70. doi:10.1016/bs.pmbts.2026.01.012.
  19. Ahmed Z. Precision medicine with multi-omics strategies, deep phenotyping, and predictive analysis. Prog Mol Biol Transl Sci. 2022;190(1):101–25. doi:10.1016/bs.pmbts.2022.02.002.
  20. Zhao J, Feng Q, Wei WQ. Integration of Omics and Phenotypic Data for Precision Medicine. Methods Mol Biol. 2022;2486:19–35. doi:10.1007/978-1-0716-2265-0_2.
  21. Gottardi Zamperla M, Barbi V, Negri S, Atlante S, Gaetano C. Omics medicine: what the clinicians should know. Eur J Intern Med. 2026;148:106759. doi:10.1016/j. ejim.2026.106759.
  22. Kant S, Deepika, Roy S. Integrative Multi-Omics and Artificial Intelligence: A New Paradigm for Systems Biology. OMICS. 2025;29(12):576–87. doi:10.1177/15578100251392371.
  23. Battineni JK, Mamidisetti YD, Kuchukuntla M, Amaravadi D, Ravula SR, Jadi RK. Mass Spectrometry Based Multi-Omics Integration: Analytical Methods and Biological Applications. Rapid Commun Mass Spectrom. 2026;40(15):e70097. doi:10.1002/rcm.70097.
  24. Wang RS, Maron BA, Loscalzo J. Multiomics Network Medicine Approaches to Precision Medicine and Therapeutics in Cardiovascular Diseases. Arterioscler Thromb Vasc Biol. 2023;43(4):493–503. doi:10.1161/ATVBAHA.122.318731.
  25. Singh S, Sarma DK, Verma V, Nagpal R, Kumar M. Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders. Biochem Biophys Res Commun. 2023;682:1–20. doi:10.1016/j.bbrc.2023.09.064.
  26. Svingel LS, Jensen CE, Kjeldsen GF, Pedersen MH, Kalra D, Christiansen CF, et al. Shaping the future EHDS: recommendations for implementation of Health Data Access Bodies in the HealthData@EU infrastructure for secondary use of electronic health data. Eur J Public Health. 2025;35(Supplement_3):iii32–8. doi:10.1093/eurpub/ckaf033.
  27. Marelli L, Stevens M, Sharon T, Van Hoyweghen I, Boeckhout M, Colussi I, et al. The European health data space: Too big to succeed? Health Policy. 2023;135:104861. doi:10.1016/j.healthpol.2023.104861.
  28. Molnár-Gábor F, Sellner J, Pagil S, Slokenberga S, Tzortzatou-Nanopoulou O, Nyström K. Harmonization after the GDPR? Divergences in the rules for genetic and health data sharing in four member states and ways to overcome them by EU measures: Insights from Germany, Greece, Latvia and Sweden. Semin Cancer Biol. 2022;84:271–83. doi:10.1016/j.semcancer.2021.12.001.
  29. Royo R, Garcia E, Schlünder I, Hilmarsen C, Thomsen MK, Cauët E, et al. Genomic data sharing in research across Europe: legal challenges and upcoming opportunities within the European Health Data Space. Eur J Public Health. 2025;35(Supplement_3):iii25–31. doi:10.1093/eurpub/ckaf070.
  30. Caudle KE, Whirl-Carrillo M, Relling MV, Hoffman JM, Donnelly RS, Haidar CE, et al. Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium (CPIC). Clin Pharmacol Ther. 2025;118(6):1512–22. doi:10.1002/cpt.70005.
  31. Landstrom AP, Ferguson JF, James CA, Key KV, Lanfear D, Natarajan P, et al. Genetic and Genomic Testing in Cardiovascular Disease: A Policy Statement From the American Heart Association. Circulation. 2025;152(24):e474–89. doi:10.1161/CIR.0000000000001385.
  32. Smith DM, Douglas MP, Aquilante CL, Deverka PA, Devine B, Dunnenberger HM, et al. Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges. Clin Pharmacol Ther. 2025;118(4):778–89. doi:10.1002/cpt.3736.
  33. Westergaard N, Lund TM, Vermehren C. Predictive Bio-markers and Personalized Therapy: Use of Pharmacogenetic Testing in a Scandinavian Perspective. Basic Clin Pharmacol Toxicol. 2025;136(3):e70009. doi:10.1111/bcpt.70009.
  34. Rojas-Salazar YL, Gómez-Montañez E, Rojas-Salazar JG. Liquid Biopsy in Modern Oncology: Advances, Challenges, and Future Perspectives in Early Cancer Detection, Minimal Residual Disease, and Dynamic Patient Monitoring. Curr Oncol Rep. 2026;28(1):59. doi:10.1007/s11912-026-01799-y.
  35. Landon BV, Annapragada AV, Niknafs N, Velculescu VE, Anagnostou V. Liquid biopsies across the cancer care continuum. Nat Med. 2025;31(12):4006–21. doi:10.1038/s41591-025-04093-9.
  36. Nguyen THH, Vu GH, Nguyen TT, Nguyen TA, Tran VU, Vu LT, et al. Combination of Hotspot Mutations With Methylation and Fragmentomic Profiles to Enhance Multi-Cancer Early Detection. Cancer Med. 2025;14(1):e70575. doi:10.1002/cam4.70575.
  37. Liu Q, Li X, Jin T, Huo S, Su S, Liu N. Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization—Clinical Evidence and Challenges. Diagn Cytopathol. 2025;53(11):580–91. doi:10.1002/dc.70009.
  38. AbdelHamid SG, Halawa EM, Ibrahim EM, ElHefnawi M. Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care. Cancer Cell Int. 2026;26(1):160. doi:10.1186/s12935-026-04263-w.
  39. Wu D, Yu Q, Wu Q, Wang X, Wei H, Li F, et al. Liquid biopsy, multi-cancer early detection, and artificial intelligence: new frontiers in cancer screening from a technological and immunological perspective. Front Immunol. 2026;17:1854718. doi:10.3389/fimmu.2026.1854718.
  40. Carr DJ, Welch HG. Assessing the Clinical Utility of Liquid Biopsies Across 5 Potential Indications From Therapy Selection to Population Screening: A Review. JAMA Intern Med. 2023;183(10):1144–51. doi:10.1001/jamainternmed.2023.3603.
  41. DeBortoli E, McGahan E, Yanes T, Berkman J, Aoude LG, Smit AK, et al. Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer. Cancer Medicine. 2025;14(15):e71080. doi:10.1002/cam4.71080.
  42. Kahn CL, Rasmussen MW, Kleif J, Pedersen IS, Therkildsen C. Blood-Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations. Int J Cancer. 2026;159(4):1028–41. doi:10.1002/ijc.70498.
  43. Duffy MJ, Crown J. Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test? Crit Rev Clin Lab Sci. 2024;61(4):241–53. doi:10.1080/10408363.2023.2275150.
  44. Liu C, Fan H, Kim M, Zhou T, Yang P, Zhao L, et al. Multimodal Wearable Biosensing Meets Multidomain AI: A Pathway to Decentralized Healthcare. Adv Sci (Weinh). 2026;13(30):e22900. doi:10.1002/advs.202522900.
  45. Ding Z, Fang W, Zhang J, Fang C, Sun Y. Artificial intelligence in wearable biosensing: Enhancing data analysis and decision-making. Prog Mol Biol Transl Sci. 2025;216:1–26. doi:10.1016/bs.pmbts.2025.06.012.
  46. Iqbal FM, Lam K, Joshi M, Khan S, Ashrafian H, Darzi A. Clinical outcomes of digital sensor alerting systems in remote monitoring: a systematic review and meta-analysis. NPJ Digit Med. 2021;4(1):7. doi:10.1038/s41746-020-00378-0.
  47. Weller GB, Mault J, Ventura ME, Adams J, Campbell FJ, Tremper KK. A Retrospective Observational Study of Continuous Wireless Vital Sign Monitoring via a Medical Grade Wearable Device on Hospitalized Floor Patients. J Clin Med. 2024;13(16):4747. doi:10.3390/jcm13164747.
  48. Phi NTT, Oikonomidi T, Ravaud P, Tran VT. Assessment of US Food and Drug Administration–Approved Digital Medical Devices for Just-in-Time Interventions: A Systematic Review. JAMA Intern Med. 2023;183(8):858–69. doi:10.1001/jamainternmed.2023.2864.
  49. Luckner S, Lauer W. [Regulatory classification of AI-enabled products for medical use on the basis of the EU AI Act and MDR/IVDR]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025;68(8):854–61. doi:10.1007/s00103-025-04091-9.
  50. Shojaei S, Yakar D, Vellinga N, Bozgo V, Kwee T, Huisman H, et al. The AI Act and the MDR post-market requirements for semiautonomous AI SaMD: a radiology case study in prostate cancer. Abdom Radiol (NY). 2026. doi:10.1007/s00261-026-05434-z.
  51. Ginsburg GS, Picard RW, Friend SH. Key Issues as Wearable Digital Health Technologies Enter Clinical Care. New England Journal of Medicine. 2024;390(12):1118–27. doi:10.1056/NEJMra2307160.
  52. Bemporad J, De Domenico F, Pozzilli P. Algor-Ethics in Diabetes Care: Mapping the Route. Diabetes/Metabolism Research and Reviews. 2026;42(2):e70139. doi:10.1002/dmrr.70139.
  53. Howard J, Schulte P. Managing workplace AI risks and the future of work. American Journal of Industrial Medicine. 2024;67(11):980–93. doi:10.1002/ajim.23653.
  54. Schmidt J, Schutte NM, Buttigieg S, Novillo-Ortiz D, Sutherland E, Anderson M, et al. Mapping the regulatory landscape for artificial intelligence in health within the European Union. NPJ Digit Med. 2024;7(1):229. doi:10.1038/s41746-024-01221-6.
  55. Niemiec E, Minssen T, Boland PA, McEntee PD, Cahill RA. Legal and regulatory challenges in multi-country data-driven projects developing and validating medical AI systems in the EU. Expert Rev Med Devices. 2025;22(9):925–37. doi:10.1080/17434440.2025.2531295.
  56. Lin JC, Jain B, Iyer JM, Rola I, Srinivasan AR, Kang C, et al. Benefit-Risk Reporting for FDA-Cleared Artificial Intelligence−Enabled Medical Devices. JAMA Health Forum. 2025;6(9):e253351. doi:10.1001/jamahealthforum.2025.3351.
  57. Chen J, Pang M, Qian W, Zhang W, Xu C, He P. Governing the rise of AI in healthcare: A comparative governance document and implementation implications across five jurisdictions. Soc Sci Med. 2026;400:119270. doi:10.1016/j. socscimed.2026.119270.
  58. Aboy M, Minssen T, Vayena E. Navigating the EU AI Act: implications for regulated digital medical products. npj Digit Med. 2024;7(1):237. doi:10.1038/s41746-024-01232-3.
  59. European Commission. Albania 2025 Report. Commission Staff Working Document SWD(2025) 750 final. Brussels: European Commission; 2025. Available at: https://enlargement.ec.europa.eu/albania-report-2025_en.
  60. Regional Cooperation Council. Western Balkans Six launch structured regional dialogue on Artificial Intelligence [Internet]. 2026. Available at: https://www.rcc.int/news/1024/western-balkans-six-launch-structured-regional-dialogue-on-artificial-intelligence.
  61. Cascella M, Avella MT, Pumpo MD, Sebastiani E, Bussa M, Tagliaferri A, et al. Artificial Intelligence in Medicine: Basic Knowledge, Applications, Ethics and Perspectives. Journal of Evaluation in Clinical Practice. 2026;32(4):e70484. doi:10.1111/jep.70484.
  62. Chin MH, Afsar-Manesh N, Bierman AS, Chang C, Colón-Rodríguez CJ, Dullabh P, et al. Guiding Principles to Address the Impact of Algorithm Bias on Racial and Ethnic Disparities in Health and Health Care. JAMA Netw Open. 2023;6(12):e2345050. doi:10.1001/jamanetworkopen.2023.45050.
  63. Ferryman K, Mackintosh M, Ghassemi M. Considering Biased Data as Informative Artifacts in AI-Assisted Health Care. New England Journal of Medicine. 2023;389(9):833–8. doi:10.1056/NEJMra2214964.
  64. World Health Organization. Ethics and governance of artificial intelligence for health: WHO guidance. Geneva: World Health Organization; 2021. Available at: https://www.who.int/publications/i/item/9789240029200.
  65. Hasan MR, Ahmed MI, Saha S, Ishika TK, Shoaib HA, Hossen MJ. Multi-modal federated learning with differential privacy for privacy-preserving healthcare AI. Sci Rep. 2026;16(1):21253. doi:10.1038/s41598-026-51804-4.
  66. Gu X, Sabrina F, Fan Z, Sohail S. A Review of Privacy Enhancement Methods for Federated Learning in Healthcare Systems. Int J Environ Res Public Health. 2023;20(15):6539. doi:10.3390/ijerph20156539.
  67. Shahsavari Y, Baseri Y, Hafid A, Dambri OA, Makrakis D. Integration of Federated Learning and Blockchain in Health Care: Tutorial on Medical Data, Architectures, Privacy, Security, and Regulatory Compliance. J Med Internet Res. 2026;28:e80178. doi:10.2196/80178.
  68. Dayan I, Roth HR, Zhong A, Harouni A, Gentili A, Abidin AZ, et al. Federated learning for predicting clinical outcomes in patients with COVID-19. Nat Med. 2021;27(10):1735–43. doi:10.1038/s41591-021-01506-3.
  69. Wichmann RM, Robiati Bigoto MA, Chiavegatto Filho ADP. Federated learning for COVID-19 mortality prediction in a multicentric sample of 21 hospitals. PLoS Comput Biol. 2025;21(11):e1013695. doi:10.1371/journal. pcbi.1013695.
  70. Sheller MJ, Edwards B, Reina GA, Martin J, Pati S, Kotrotsou A, et al. Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data. Sci Rep. 2020;10(1):12598. doi:10.1038/s41598-020-69250-1.
  71. Cheung ATM, Nasir-Moin M, Fred Kwon YJ, Guan J, Liu C, Jiang L, et al. Methods and Impact for Using Federated Learning to Collaborate on Clinical Research. Neurosurgery. 2023;92(2):431–8. doi:10.1227/neu.0000000000002198.
  72. Shahid MI, Badar HMS, Asghar MN, Abdullah A. Health-FedNet: secure federated learning for chronic disease prediction on MIMIC-III with differential privacy and homomorphic encryption. Sci Rep. 2026;16(1):7968. doi:10.1038/s41598-026-36034-y.
  73. de Arruda Botelho Herr M, Placzek P, Abu Attieh H, Schultz B, Hieber D, Röhl A, et al. Enabling Privacy-Preserving Federated Learning in Healthcare: The FLAME Architecture and Policy Framework. Stud Health Technol Inform. 2026;336:1589–90. doi:10.3233/SHTI260485.
  74. Li S, Liu P, Nascimento GG, Wang X, Leite FRM, Chakraborty B, et al. Federated and distributed learning applications for electronic health records and structured medical data: a scoping review. J Am Med Inform Assoc. 2023;30(12):2041–9. doi:10.1093/jamia/ocad170.
  75. Qiu X, Parcollet T, Fernandez-Marques J, Gusmao PP, Gao Y, Beutel DJ, et al. A first look into the carbon footprint of federated learning. Journal of Machine Learning Research. 2023;24(129):1–23.
  76. Chatzichristos C, Chatzichristos G, Borremans I, Gruyaert S, De Vos I, De Vos M, et al. Bridging the AI-Literacy Gap in Health Care: Qualitative Analysis of the Flanders Case Study. J Med Internet Res. 2025;27:e76709. doi:10.2196/76709.
  77. Gorga A, Barbati C, Airapetian M, Briganti GL, Carnevali ED, Cervellera F, et al. Mapping digital public health training: are we preparing the European work-force? Front Public Health. 2026;14:1778953. doi:10.3389/fpubh.2026.1778953.
  78. Solomonides AE, Koski E, Atabaki SM, Weinberg S, McGreevey JD, Kannry JL, et al. Defining AMIA’s artificial intelligence principles. J Am Med Inform Assoc. 2022;29(4):585–91. doi:10.1093/jamia/ocac006.
  79. Crowe B, Shah S, Teng D, Ma SP, DeCamp M, Rosenberg EI, et al. Recommendations for Clinicians, Technologists, and Healthcare Organizations on the Use of Generative Artificial Intelligence in Medicine: A Position Statement from the Society of General Internal Medicine. J Gen Intern Med. 2025;40(3):694–702. doi:10.1007/s11606-024-09102-0.
  80. Ayoub NF, Rameau A, Brenner MJ, Bur AM, Ator GA, Briggs SE, et al. American Academy of Otolaryngology– Head and Neck Surgery (AAO-HNS) Report on Artificial Intelligence. Otolaryngology–Head and Neck Surgery. 2025;172(2):734–43. doi:10.1002/ohn.1080.
  81. Kalodanis K, Feretzakis G, Rizomiliotis P, Verykios VS, Papapavlou C, Skrekas A, et al. Evaluating the Impact of the EU AI Act on Medical Device Regulation. Stud Health Technol Inform. 2025;323:40–4. doi:10.3233/SHTI250045.
  82. Haj Mohammad SF, van der Pol H, Vrdoljak E, Lassen U, Ojamaa K, Jalkanen K, et al. A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium. ESMO Open. 2025;10(11):105872. doi:10.1016/j. esmoop.2025.105872.
  83. International Medical Device Regulators Forum (IMDRF). Artificial Intelligence/Machine Learning-enabled Working Group. Available at: https://www.imdrf.org/working-groups/artificial-intelligencemachine-learning-enabled.
  84. European Commission. Targeted consultation on the draft guidelines for the classification of high-risk artificial intelligence systems. 2026. Available at: https://digital-strategy.ec.europa.eu/en/consultations/targeted-consultation-draft-guidelines-classification-high-risk-artificial-intelligence-systems.
  85. Swen JJ, van der Wouden CH, Manson LEN, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347–56. doi:10.1016/S0140-6736(22)01841-4.
  86. Lång K, Josefsson V, Larsson AM, Larsson S, Högberg C, Sartor H, et al. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. Lancet Oncol. 2023;24(8):936–44. doi:10.1016/S1470-2045(23)00298-X.
  87. European Parliament and Council of the European Union. Regulation (EU) 2024/1689 laying down harmonised rules on artificial intelligence (Artificial Intelligence Act), consolidated version of 27 July 2026 [Internet]. [cited 2026 Oct 10]. Available from: [EUR-Lex](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX-:02024R1689-20260727).
  88. European Parliament and Council of the European Union. Regulation (EU) 2017/745 on medical devices [Internet]. 2017 [cited 2026 Oct 10]. Available from: [EUR-Lex] (https://eur-lex.europa.eu/eli/reg/2017/745/oj/eng).
  89. European Parliament and Council of the European Union. Regulation (EU) 2017/746 on in vitro diagnostic medical devices [Internet]. 2017 [cited 2026 Oct 10]. Available from: [EUR-Lex](https://eur-lex.europa.eu/eli/reg/2017/746/oj/eng).
  90. European Parliament and Council of the European Union. Regulation (EU) 2016/679 (General Data Protection Regulation) [Internet]. 2016 [cited 2026 Oct 10]. Available from: [EUR-Lex](https://eur-lex.europa.eu/eli/reg/2016/679/oj/eng).
  91. European Parliament and Council of the European Union. Directive (EU) 2024/2853 on liability for defective products [Internet]. 2024 [cited 2026 Oct 10]. Available from: [EUR-Lex](https://eur-lex.europa.eu/eli/dir/2024/2853/oj/eng).
  92. European Parliament and Council of the European Union. Regulation (EU) 2025/327 on the European Health Data Space [Internet]. 2025 [cited 2026 Oct 10]. Available from: [EUR-Lex](https://eur-lex.europa.eu/eli/reg/2025/327/oj/eng).
  93. European Medicines Agency. Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle. EMA/CHMP/CVMP/83833/2023 [Internet]. 2024 [cited 2026 Oct 10]. Available from: [EMA](https://www.ema.europa.eu/system/files/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle-en.pdf).
  94. European Commission. EUDAMED: four first modules will be mandatory to use as of 28 May 2026 [Internet]. 2025 Nov 27 [cited 2026 Oct 10]. Available from: [European Commission](https://health.ec.europa.eu/latest-updates/eudamed-four-first-modules-will-be-mandatory-use-28-may-2026-2025-11-27_en).
  95. Federal Institute for Drugs and Medical Devices. DiGA overview: directory and assessment under section 139e SGB V [Internet]. [cited 2026 Oct 10]. Available from: [BfArM](https://fhir.bfarm.de/guide/diga-overview-en.html).
  96. National Institute for Health and Care Excellence. Evidence standards framework for digital health technologies [Internet]. 2022 [cited 2026 Oct 10]. Available from: [NICE] (https://www.nice.org.uk/corporate/ecd7/resources/evidence-standards-framework-for-digital-health-technologies-pdf-1124017457605).
  97. US Food and Drug Administration. Marketing submission recommendations for a predetermined change control plan for artificial intelligence-enabled device software functions: guidance for industry and Food and Drug Administration staff [Internet]. 2025 Aug 18 [cited 2026 Oct 10]. Available from: [FDA](https://www.fda.gov/media/166704/download).
  98. European Parliament and Council of the European Union. Regulation (EU) 2026/1744 amending Regulations (EU) 2024/1689, (EU) 2018/1139 and (EU) 2023/1230 as regards the simplification of the implementation of harmonised rules on artificial intelligence (Digital Omnibus on AI) [Internet]. 2026 [cited 2026 Oct 10]. Available from: [EUR-Lex](https://eur-lex.europa.eu/eli/reg/2026/1744/oj/eng).
Language: English
Page range: 270 - 286
Published online: Oct 31, 2026
Published in print: Oct 1, 2026
Published by: European Biotechnology Thematic Network Association
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Luca Ferrari, Muhammad Imran, Beatrice Della Frera, Ahmad Jainul Abidin, Tommaso Beccari, Nuriye Gokce, Štefánia Hrončeková, Hilal Akalin, Satya Prakash, Ed Judge, Dominika Vešelényiová, Martin Koller, Kosi Gramatikoff, Oscar Vicente, Izabela Radecka, Robert S. Marks, Ratnesh Lal, Michel Salzet, Kisung Ko, Michele Maffia, Isabelle Fournier, Lejla Pojskic, Qun Sun, Lembit Nei, Reynir Arngrimsson, Gary Henehan, Irina Nakashidze, Dijana Plaseska-Karanfilska, Karla Santacruz-Gomez, Dana Tapaloaga, Andreas Janecke, Ivana Márová, Ariola Bacu, Alexander Kilchevsky, Anita Slavica, Jose Carlos Lorenzo Feijoo, Andrés Izquierdo Romero, Bajram Berisha, Mark Nuijten, Nikolai Zhelev, Mario Petrov Milkov, Svetlana Fotkova Georgieva, Luis Izquierdo Lopez, Juraj Krajcovic, Saharuddin Bin Mohamad, Fideline Tchuenbou-Magaia, Donald K. Martin, Isabel Belo, Fabrizio Bruschi, A. Baki Yildirim, Recep Eroz, Victor Revin, Anargyros N. Moulas, M. Sait Dundar, Paolo Bartolini, Helal Ragab Moussa, Amin Hejazi, Attya Bhatti, Alma Kokhmetova, Viktor Nedovic, Alla Salmina, Majeti Narasimha Vara Prasad, Alena Mikhalenka, Serghei Sprincean, Adam Mechler, Munis Dundar, Matteo Bertelli, published by European Biotechnology Thematic Network Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.